

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	21303Y
First Inventor or Application Identifier	Dai-Shi Su
Title	2-QUINOXALINONE DERIVATIVES AS BRADYKININ ANTAGONISTS AND NOVEL COMPOUNDS
Express Mail Label No.	EV 321984590 US

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.	ADDRESS TO: Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450
1. <input checked="" type="checkbox"/> Fee Transmittal Form (Submit an original, and a duplicate for fee processing)	6. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
2. <input checked="" type="checkbox"/> Specification [Total Pages <input type="text" value="67"/>]	a. <input type="checkbox"/> Computer Readable Form (CRF)
3. <input type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets <input type="text"/>]	b. <input type="checkbox"/> Specification Sequence Listing on: i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or ii. <input type="checkbox"/> paper
4. Oath or Declaration	c. <input type="checkbox"/> Statements verifying identity of above copies
a. <input type="checkbox"/> Newly executed (original or copy)	
b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 14 completed)	
i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33 (b).	
5. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76	

ACCOMPANYING APPLICATION PARTS

- | | |
|---|--|
| 7. <input type="checkbox"/> Assignment papers (cover sheet & document(s)) | |
| 8. <input type="checkbox"/> 37 CFR 3.73(b) Statement
(when there is an assignee) | <input type="checkbox"/> Power of Attorney |
| 9. <input type="checkbox"/> Information Disclosure Statement
(IDS)/PTO-1449 | <input type="checkbox"/> Copies of IDS Citations |
| 10. <input type="checkbox"/> Preliminary Amendment | |
| 11. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503)
(Should be specifically itemized) | |
| 12. <input type="checkbox"/> Certified Copy of Priority Document(s)
(if foreign priority is claimed) | |
| 13. <input checked="" type="checkbox"/> Other: <u>Unsigned Declaration and Power of Attorney</u> | |

14. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:


<input type="checkbox"/> Continuation	<input type="checkbox"/> Divisional	<input type="checkbox"/> Continuation-in-part (CIP)	of prior application No. ____ / ____
Prior application information: Examiner: _____			Group/Art Unit: _____

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.

15. CORRESPONDENCE ADDRESS☒ Customer Number or Bar Code Label**Customer No. 000210**

(Insert Customer No. or Attach bar code here)

NAME	Mollie M. Yang				
ADDRESS	Merck & Co., Inc., P. O. Box 2000 - Patent Dept., RY60-30				
CITY	Rahway	STATE	NJ	ZIP CODE	07065-0907
COUNTRY	USA	TELEPHONE	732-594- 6343	FAX	732-594-4720

Name	Mollie M. Yang	Registration No. (Attorney/Agent)	32,718
Signature		Date	7/7/2003

EXPRESS MAIL CERTIFICATEDATE OF DEPOSIT July 7, 2003EXPRESS MAIL NO. EV 321984590 US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

MAILED BY Ron SchepersDATE July 7, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Deposit Acct. 13-2755
MERCK & CO., INC.
Our Case Docket No. 21303Y

Sir:

Transmitted herewith for filing under 37 C.F.R. §1.53(b) is the patent application of Inventor(s):
Dai-Shi Su and Mark G. Bock

For: 2-QUINOXALINONE DERIVATIVES AS BRADYKININ ANTAGONISTS AND NOVEL COMPOUNDS

For	Number Filed	Number Extra	Rate	Basic F \$750
Total Claims	11 - 20 =	0 X	\$18	= \$0
Independent Claims	4 - 3 =	1 X	\$84	= \$84
Multiple Dependent Claims*			\$280	=
* Add this fee if application contains any multiple dependent claims, regardless of number.		TOTAL FILING FEE →		\$834

Please charge my Deposit Account No. 13-2755 in the amount of \$ 834. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Account No. 13-2755. Duplicate copy of this sheet is enclosed.

☒ Under the provisions of 37 C.F.R. §1.53, this application is being filed without the declaration of each inventor.

Respectfully,

Mollie M. Yang
By: Mollie M. Yang

Attorney For Applicant(s)

Reg. No. 32,718

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732) 594-6343

Date: July 7, 2003

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT July 7, 2003

EXPRESS MAIL NO. EV 321984590 US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

MAILED BY *Ron Schepise* DATE July 7, 2003

IN DUPLICATE